Infiltrative Lung Diseases: Complications of Novel Antineoplastic Agents in Patients with Hematological Malignancies
Infiltrative lung disease is a well-known complication of antineoplastic agents in patients with hematological malignancies. Novel agents are constantly being added to available treatments. The present review discusses different pulmonary syndromes, pathogenesis and management of these novel agents.
Saved in:
Main Authors: | Bobbak Vahid, Paul E Marik |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2008-01-01
|
Series: | Canadian Respiratory Journal |
Online Access: | http://dx.doi.org/10.1155/2008/305234 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oncolytic Virotherapy for Hematological Malignancies
by: Swarna Bais, et al.
Published: (2012-01-01) -
Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies
by: Scott Wadler
Published: (1994-01-01) -
Antineoplastic Effects of 5-Aminosalicylates and Potential Cancer Preventive Role in Inflammatory Bowel Disease
by: Hugh J Freeman
Published: (2004-01-01) -
Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy
by: Pradyumna Agasthi, et al.
Published: (2018-01-01) -
GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE
by: Francesco Fabozzi, et al.
Published: (2023-04-01)